Patient-specific models link neurotransmitter receptor mechanisms with motor and visuospatial axes of Parkinson's disease.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
26 09 2023
26 09 2023
Historique:
received:
28
02
2023
accepted:
08
09
2023
medline:
20
11
2023
pubmed:
27
9
2023
entrez:
26
9
2023
Statut:
epublish
Résumé
Parkinson's disease involves multiple neurotransmitter systems beyond the classical dopaminergic circuit, but their influence on structural and functional alterations is not well understood. Here, we use patient-specific causal brain modeling to identify latent neurotransmitter receptor-mediated mechanisms contributing to Parkinson's disease progression. Combining the spatial distribution of 15 receptors from post-mortem autoradiography with 6 neuroimaging-derived pathological factors, we detect a diverse set of receptors influencing gray matter atrophy, functional activity dysregulation, microstructural degeneration, and dendrite and dopaminergic transporter loss. Inter-individual variability in receptor mechanisms correlates with symptom severity along two distinct axes, representing motor and psychomotor symptoms with large GABAergic and glutamatergic contributions, and cholinergically-dominant visuospatial, psychiatric and memory dysfunction. Our work demonstrates that receptor architecture helps explain multi-factorial brain re-organization, and suggests that distinct, co-existing receptor-mediated processes underlie Parkinson's disease.
Identifiants
pubmed: 37752107
doi: 10.1038/s41467-023-41677-w
pii: 10.1038/s41467-023-41677-w
pmc: PMC10522603
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Receptors, Neurotransmitter
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6009Informations de copyright
© 2023. The Author(s).
Références
Alexander, G. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin. Neurosci. 6, 259–280 (2004).
pubmed: 22033559
pmcid: 3181806
doi: 10.31887/DCNS.2004.6.3/galexander
Han, J. et al. Psychiatric manifestation in patients with Parkinson’s disease. J. Korean Med. Sci. 33, e300 (2018).
pubmed: 30450025
pmcid: 6236081
doi: 10.3346/jkms.2018.33.e300
Jellinger, K. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts,”. Mov. Disord. 27, 8–30 (2012).
Titova, N., Lewis, S., Padmakumar, C. & Chaudhuri, K. Parkinson’s: a syndrome rather than a disease? J. Neural Transmission 124, 907–914 (2017).
Sauerbier, A., Qamar, M., Rajah, T. & Chaudhuri, K. New concepts in the pathogenesis and presentation of Parkinson’s disease. Clin. Med. 16, 365 (2016).
doi: 10.7861/clinmedicine.16-4-365
von Coelln, R. & Shulman, L. Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr. Opin. Neurol. 29, 727–734 (2016).
doi: 10.1097/WCO.0000000000000384
Oertel, W. & Schulz, J. B. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J. Neurochem. 139, 325–337 (2016).
pubmed: 27577098
doi: 10.1111/jnc.13750
Brichta, L., Greengard, P. & Flajolet, M. Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. Trends Neurosci. 36, 543–554 (2013).
pubmed: 23876424
doi: 10.1016/j.tins.2013.06.003
Espay, A. et al. Levodopa‐induced dyskinesia in Parkinson disease: current and evolving concepts. Ann. Neurol. 84, 797–811 (2018).
pubmed: 30357892
doi: 10.1002/ana.25364
Adler, C. et al. Low clinical diagnostic accuracy of early vs. advance Parkinson disease (Clinicopathologic study). Neurology 83, 406–412 (2014).
pubmed: 24975862
pmcid: 4132570
doi: 10.1212/WNL.0000000000000641
Pagano, G., Niccolini, F. & Politis, M. Imaging in Parkinson’s disease. Clin. Med. 16, 371 (2016).
doi: 10.7861/clinmedicine.16-4-371
Ellis, J. & Fell, M. Current approaches to the treatment of Parkinson’s Disease. Bioorg. Med. Chem. Lett. 27, 4247–4255 (2017).
pubmed: 28869077
doi: 10.1016/j.bmcl.2017.07.075
LeWitt, P. A. & Chaudhuri, K. Unmet needs in Parkinson disease: Motor and non-motor. Parkinsonism Related Disord. 80, S7–S12 (2020).
doi: 10.1016/j.parkreldis.2020.09.024
Xu, Y. et al. Neurotransmitter receptors and cognitive dysfunction in alzheimer’s disease and parkinson’s disease. Prog. Neurobiol. 97, 1–13 (2012).
pubmed: 22387368
pmcid: 3371373
doi: 10.1016/j.pneurobio.2012.02.002
Shang, S. et al. Region-Specific neurovascular decoupling associated with cognitive decline in parkinson’s disease. Front. Aging Neurosci. 13, 770528 (2021).
pubmed: 34867297
pmcid: 8636132
doi: 10.3389/fnagi.2021.770528
Zarkali, A. et al. Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson’s disease. Commun. Biol. 4, 1–13 (2021).
doi: 10.1038/s42003-020-01622-9
Halliday, G. M., Leverenz, J. B., Schneider, J. S. & Adler, C. H. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov. Disord. 29, 634–650 (2014).
pubmed: 24757112
pmcid: 4049032
doi: 10.1002/mds.25857
Kehagia, A. A., Barker, R. A. & Robbins, T. W. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegenerative Dis. 11, 79–92 (2013).
doi: 10.1159/000341998
Bohnen, N. et al. Cholinergic system changes in Parkinson’s disease: emerging therapeutic approaches. Lancet Neurol. 21, 381–392 (2022).
pubmed: 35131038
pmcid: 8985079
doi: 10.1016/S1474-4422(21)00377-X
Politis, M. & Niccolini, F. Serotonin in Parkinson’s Disease. Behav. Brain Res. 277, 136–145 (2015).
pubmed: 25086269
doi: 10.1016/j.bbr.2014.07.037
Grimbergen, Y., Langston, J., Roos, R. & Bloem, B. Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev. Neurother. 9, 279–290 (2009).
pubmed: 19210201
doi: 10.1586/14737175.9.2.279
Weingarten, C., Sundman, M., Hickey, P. & Chen, N. Neuroimaging of Parkinson’s disease: Expanding views. Neurosci. Biobehav. Rev. 59, 16–52 (2015).
pubmed: 26409344
pmcid: 4763948
doi: 10.1016/j.neubiorev.2015.09.007
Bidesi, N., Vang Andersen, I., Windhorst, A., Shalgunov, V. & Herth, M. The role of neuroimaging in Parkinson’s disease. J. Neurochem. 159, 660–689 (2021).
pubmed: 34532856
pmcid: 9291628
doi: 10.1111/jnc.15516
Atkinson-Clement, C. et al. Diffusion tensor imaging in Parkinson’s disease: review and meta-analysis. NeuroImage: Clinical 16, 98–110 (2017).
pubmed: 28765809
doi: 10.1016/j.nicl.2017.07.011
Lin, S. et al. Neuroimaging signatures predicting motor improvement to focused ultrasound subthalamotomy in Parkinson’s disease. npj Parkinson’s Dis. 8, 70 (2022).
doi: 10.1038/s41531-022-00332-9
Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).
pubmed: 23332364
pmcid: 3622225
doi: 10.1016/S1474-4422(12)70291-0
Iturria-Medina, Y. et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat. Commun. 7, 1–14 (2016).
doi: 10.1038/ncomms11934
Lenglos, C. et al. Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson’s disease. Sci. Rep. 12, 5483 (2022).
pubmed: 35361840
pmcid: 8971452
doi: 10.1038/s41598-022-09506-0
Iturria-Medina, Y., Carbonell, F. M., Sotero, R. C., Chouinard-Decorte, F. & Evans, A. C. Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer’s disease. NeuroImage 152, 60–77 (2017).
pubmed: 28257929
doi: 10.1016/j.neuroimage.2017.02.058
Iturria-Medina, Y., Carbonell, F. M. & Evans, A. C. Multimodal imaging-based therapeutic fingerprints for optimizing personalized interventions: Application to neurodegeneration. NeuroImage 179, 40–50 (2018).
pubmed: 29894824
doi: 10.1016/j.neuroimage.2018.06.028
Zilles, K. & Palomero-Gallagher, N. Multiple transmitter receptors in regions and layers of the human cerebral cortex. Front. Neuroanatomy 11, 78 (2017).
doi: 10.3389/fnana.2017.00078
Khan, A. et al. Personalized brain models identify neurotransmitter receptor changes in Alzheimer’s disease. Brain 145, 1785–1804 (2022).
pubmed: 34605898
doi: 10.1093/brain/awab375
Mühlau, M. T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No. Multiple Sclerosis J. 28, 355–356 (2022).
doi: 10.1177/13524585211063622
Righart, R. et al. Cortical pathology in multiple sclerosis detected by the T 1/T 2‐weighted ratio from routine magnetic resonance imaging. Ann. Neurol. 82, 519–529 (2017).
pubmed: 28833433
pmcid: 5698772
doi: 10.1002/ana.25020
Kiely, K., Butterworth, P., Watson, N. & Wooden, M. The Symbol Digit Modalities Test: Normative data from a large nationally representative sample of Australian. Arch. Clin. Neuropsychol. 29, 767–775 (2014).
pubmed: 25352087
doi: 10.1093/arclin/acu055
Pagano, G., Niccolini, F. & Politis, M. Imaging in Parkinson’s disease,”. Clin. Med. 16, 371 (2016).
doi: 10.7861/clinmedicine.16-4-371
Bohnen, N. I. et al. Progression of regional cortical cholinergic denervation in Parkinson’s disease. Brain Commun. 4, fcac320 (2022).
pubmed: 36569603
doi: 10.1093/braincomms/fcac320
Chiu, W. et al. Multireceptor fingerprints in progressive supranuclear palsy. Alzheimer’s Res. Ther. 9, 1–13 (2017).
Zimmermann, J. et al. Differentiation of Alzheimer’s disease based on local and global parameters in personalized Virtual Brain models. NeuroImage: Clinical 19, 240–251 (2018).
pubmed: 30035018
doi: 10.1016/j.nicl.2018.04.017
Adewale, Q., Khan, A., Carbonell, F. & Iturria-Medina, Y. Integrated transcriptomic and neuroimaging brain model decodes biological mechanisms in aging and Alzheimer’s disease. Elife 10, e62589 (2021).
pubmed: 34002691
pmcid: 8131100
doi: 10.7554/eLife.62589
Ballentine, G., Friedman, S. & Bzdok, D. Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences. Sci. Adv. 8, eabl6989 (2022).
Zachlod, D., Bludau, S., Cichon, S., Palomero-Gallagher, N. & Amunts, K. Combined analysis of cytoarchitectonic, molecular and transcriptomic patterns reveal differences in brain organization across human functional brain systems. NeuroImage 257, 119286 (2022).
Hansen, J. et al. Correspondence between gene expression and neurotransmitter receptor and transporter density in the human brain. NeuroImage 264, 119671 (2021).
Pak, K. et al. Limited power of dopamine transporter mRNA mapping for predicting dopamine transporter availability. Synapse 76, e22226 (2022).
pubmed: 35104380
doi: 10.1002/syn.22226
Dukart, J. et al. JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. Human Brain Mapping 42, 555–566 (2020).
pubmed: 33079453
pmcid: 7814756
doi: 10.1002/hbm.25244
Sakreida, K. et al. Disentangling dyskinesia from parkinsonism in motor structures of patients with schizophrenia. Brain Commun. 4, fcac190 (2022).
pubmed: 35912135
pmcid: 9337227
doi: 10.1093/braincomms/fcac190
Premi, E. et al. Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study. Neurobiol. Dis. 179, 106068 (2023).
pubmed: 36898614
doi: 10.1016/j.nbd.2023.106068
Hahn, L. et al. Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems. medRxiv, 2022-08 (2022).
Dukart, J. et al. Cerebral blood flow predicts differential neurotransmitter activity. Sci. Rep. 8, 1–11 (2018).
doi: 10.1038/s41598-018-22444-0
Moses, W. Fundamental limits of spatial resolution in PET. Nuc. Instruments Methods Phys. Res. Sec. A: Accelerators, Spectrometers, Detectors Assoc. Equip. 648, S236–S240 (2011).
doi: 10.1016/j.nima.2010.11.092
Mak, E., Su, L., Williams, G. & O’Brien, J. Neuroimaging correlates of cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat. Disord. 21, 862–870 (2015).
pubmed: 26004683
doi: 10.1016/j.parkreldis.2015.05.013
Zhan, W. et al. Regional alterations of brain microstructure in Parkinson’s disease using diffusion tensor imaging. Mov. Disord. 27, 90–97 (2012).
pubmed: 21850668
doi: 10.1002/mds.23917
Tang, Y. et al. Identifying the presence of Parkinson’s disease using low-frequency fluctuations in BOLD signals. Neurosci. Lett. 645, 1–6 (2017).
pubmed: 28249785
doi: 10.1016/j.neulet.2017.02.056
Nguyen, K. et al. Predicting Parkinson’s disease trajectory using clinical and neuroimaging baseline measures. Parkinsonism Related Disord. 85, 44–51 (2021).
doi: 10.1016/j.parkreldis.2021.02.026
Markello, R. & Misic, B. Comparing spatial null models for brain maps. NeuroImage 236, 118052 (2021).
pubmed: 33857618
doi: 10.1016/j.neuroimage.2021.118052
Assaf, Y. “Imaging laminar structures in the gray matter with diffusion MRI,”. Neuroimage 197, 677–688 (2019).
pubmed: 29309898
doi: 10.1016/j.neuroimage.2017.12.096
Weston, P., Simpson, I., Ryan, N., Ourselin, S. & Fox, N. Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration. Alzheimer’s Res. Ther. 7, 1–8 (2015).
Cercignani, M., Inglese, M., Pagani, E., Comi, G. & Filippi, M. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. Am. J. Neuroradiol. 22, 952–958 (2001).
pubmed: 11337342
pmcid: 8174941
Bergamino, M., Keeling, E., Mishra, V., Stokes, A. & Walsh, R. Assessing white matter pathology in early-stage Parkinson disease using diffusion MRI: a systematic review. Front. Neurol. 11, 314 (2020).
pubmed: 32477235
pmcid: 7240075
doi: 10.3389/fneur.2020.00314
Fu, H., Hardy, J. & Duff, K. Selective vulnerability in neurodegenerative diseases. Nat. Neurosci. 21, 1350–1358 (2018).
pubmed: 30250262
pmcid: 6360529
doi: 10.1038/s41593-018-0221-2
Volkow, N. et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcoholism: Clin. Exp. Res. 20, 1594–1598 (1996).
doi: 10.1111/j.1530-0277.1996.tb05936.x
Thobois, S., Prange, S., Scheiber, C. & Broussolle, E. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. Parkinsonism Related Disord. 59, 93–100 (2019).
doi: 10.1016/j.parkreldis.2018.08.016
Bu, M., Farrer, M. & Khoshbouei, H. Dynamic control of the dopamine transporter in neurotransmission and homeostasis. NPJ Parkinson’s Dis. 7, 1–11 (2021).
Kerstens, V. & Varrone, A. Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT. Clin. Transl. Imaging 8, 349–356 (2020).
doi: 10.1007/s40336-020-00386-w
Zeighami, Y. et al. Network structure of brain atrophy in de novo Parkinson’s disease. eLife 4, e08440 (2015).
pubmed: 26344547
pmcid: 4596689
doi: 10.7554/eLife.08440
Ruppert, M. C. et al. Network degeneration in Parkinson’s disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain 143, 944–959 (2020).
pubmed: 32057084
doi: 10.1093/brain/awaa019
Caudle, W. & Zhang, J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp. Neurol. 220, 230–233 (2009).
pubmed: 19815009
doi: 10.1016/j.expneurol.2009.09.027
Zhang, Z. et al. Roles of glutamate receptors in Parkinson’s disease. Int. J. Mol. Sci. 20, 4391 (2019).
pubmed: 31500132
pmcid: 6769661
doi: 10.3390/ijms20184391
Firbank, M. et al. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology 91, e675–e685 (2018).
pubmed: 30021920
pmcid: 6105043
doi: 10.1212/WNL.0000000000006007
Calabresi, P., Picconi, B., Parnetti, L. & Di Filippo, M. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine–acetylcholine synaptic balance. Lancet Neurol. 5, 974–983 (2006).
pubmed: 17052664
doi: 10.1016/S1474-4422(06)70600-7
Vegas-Suarez, S. et al. Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia. Int. Rev. Neurobiol. 146, 259–279 (2019).
pubmed: 31349930
doi: 10.1016/bs.irn.2019.06.013
Ballanger, B. et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67, 416–421 (2010).
pubmed: 20385906
doi: 10.1001/archneurol.2010.35
Nelson, A., Hoque, T., Gunraj, C. & Chen, R. Altered somatosensory processing in Parkinson’s disease and modulation by dopaminergic medications. Parkinsonism Related Disord. 53, 76–81 (2018).
doi: 10.1016/j.parkreldis.2018.05.002
Müller, M. & Bohnen, N. Cholinergic dysfunction in Parkinson’s disease. Curr. Neurol. Neurosci. Rep. 13, 1–9 (2013).
doi: 10.1007/s11910-013-0377-9
Quik, M. & Kulak, J. Nicotine and nicotinic receptors; relevance to Parkinson’s disease,”. Neurotoxicology 23, 581–594 (2002).
pubmed: 12428730
doi: 10.1016/S0161-813X(02)00036-0
Fujita, M. et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease. Ann. Neurol. 59, 174–177 (2006).
pubmed: 16374823
pmcid: 1351078
doi: 10.1002/ana.20688
Lester, D., Rogers, T. & Blaha, C. Acetylcholine–dopamine interactions in the pathophysiology and treatment of CNS disorders, CNS Neurosci. Ther. 16, 137–162 (2010).
pubmed: 20370804
pmcid: 6493877
doi: 10.1111/j.1755-5949.2010.00142.x
Schlicker, E. & Feuerstein, T. Human presynaptic receptors. Pharmacol. Ther. 172, 1–21 (2017).
pubmed: 27902931
doi: 10.1016/j.pharmthera.2016.11.005
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., Calne, D. & Stoessl, A. Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model. Brain 127, 888–899 (2004).
pubmed: 14960500
doi: 10.1093/brain/awh102
Chu, J., Wagle-Shukla, A., Gunraj, C., Lang, A. & Chen, R. Impaired presynaptic inhibition in the motor cortex in Parkinson disease. Neurology 72, 842–849 (2009).
pubmed: 19255412
doi: 10.1212/01.wnl.0000343881.27524.e8
Sterling, N. et al. Stage-dependent loss of cortical gyrification as Parkinson disease “unfolds”. Neurology 86, 1143–1151 (2016).
pubmed: 26888982
pmcid: 4820131
doi: 10.1212/WNL.0000000000002492
Zhang, Y. et al. Cortical gyrification reductions and subcortical atrophy in Parkinson’s disease. Mov. Disord. 29, 122–126 (2014).
pubmed: 24123500
doi: 10.1002/mds.25680
Jamebozorgi, K. et al. Cellular and molecular aspects of Parkinson treatment: future therapeutic perspectives, Mol. Neurobiol. 56, 4799–4811 (2019).
Sled, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Transact. Med. Imaging 17, 87–97 (1998).
doi: 10.1109/42.668698
Evans, A. C., Kamber, M., Collins, D. & MacDonald, D. An MRI-based probabilistic atlas of neuroanatomy. in Magn. Reson. Scanning Epilepsy. (ed. Shorvon, S. D. et al) 263–274, (Springer, Boston, 1994).
Ashburner, J. A fast diffeomorphic image registration algorithm. NeuroImage 38, 95–113 (2007).
pubmed: 17761438
doi: 10.1016/j.neuroimage.2007.07.007
Yan, C. & Zang, Y. DPARSF: A matlab toolbox for “pipeline” data analysis of resting-state fMRI. Front. Syst. Neurosci. 4, 13 (2010).
Aiello, M. et al. Relationship between simultaneously acquired resting-state regional cerebral glucose metabolism and functional MRI: a PET/MR hybrid scanner study. Neuroimage 113, 111–121 (2015).
pubmed: 25791784
doi: 10.1016/j.neuroimage.2015.03.017
Zou, Q.-H. et al. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: Fractional ALFF. J. Neurosci. Methods 172, 137–141 (2008).
pubmed: 18501969
pmcid: 3902859
doi: 10.1016/j.jneumeth.2008.04.012
Rohde, G. et al. Comprehensive approach for correction of motion and distortion in diffusion‐weighted MRI. Magnetic Resonance in Medicine: Magn. Reson. Med.: Magn. Reson. Med.: Off. J. Int. Soc. Magn. Reson. Med. 51, 103–114 (2004).
doi: 10.1002/mrm.10677
Palomero-Gallagher, N. & Zilles, K. Cyto-and receptor architectonic mapping of the human brain,”. Handbook Clin. Neurol. 150, 355–387 (2018).
doi: 10.1016/B978-0-444-63639-3.00024-4
Merker, B. Silver staining of cell bodies by means of physical development. J. Neurosci. Methods 9, 235–241 (1983).
pubmed: 6198563
doi: 10.1016/0165-0270(83)90086-9
Eickhoff, S. et al. Assignment of functional activations to probabilistic cytoarchitectonic areas revisited. NeuroImage 36, 511–521 (2007).
pubmed: 17499520
doi: 10.1016/j.neuroimage.2007.03.060
Brodmann, K. Vergleichende Lokalisationslehre der Großhirnrinde in ihren Prinzipien dargestellt auf Grund des Zellenbaues (Barth, Leipzig, 1909); English translation available in Garey, L. J. Brodmann’s Localization in the Cerebral Cortex (Smith Gordon, London, 1994).
Rolls, E., Huang, C., Lin, C., Feng, J. & Joliot, M. Automated anatomical labelling atlas 3. Neuroimage 206, 116189 (2020).
pubmed: 31521825
doi: 10.1016/j.neuroimage.2019.116189
Ewert, S. et al. Toward defining deep brain stimulation targets in MNI space: a subcortical atlas based on multimodal MRI, histology and structural connectivity. Neuroimage 170, 271–282 (2018).
pubmed: 28536045
doi: 10.1016/j.neuroimage.2017.05.015
Jenkinson, M., Beckmann, C., Behrens, T., Woolrich, M. & Smith, S. FSL. NeuroImage 62, 782–790 (2012).
pubmed: 21979382
doi: 10.1016/j.neuroimage.2011.09.015
Yeh, F. et al. Population-averaged atlas of the macroscale human structural connectome and its network topology. NeuroImage 178, 57–68 (2018).
pubmed: 29758339
doi: 10.1016/j.neuroimage.2018.05.027
Yeh, F. & Tseng, W. I. NTU-90: A high angular resolution brain atlas constructed by q-space diffeomorphic reconstruction. NeuroImage 58, 91–99 (2011).
pubmed: 21704171
doi: 10.1016/j.neuroimage.2011.06.021
Yeh, F., Wedeen, V. J. & Tseng, W.-Y. I. Generalized q-sampling imaging. IEEE Transact. Med. Imaging 29, 1626–1635 (2010).
doi: 10.1109/TMI.2010.2045126
Yeh, F., Liu, L., Hitchens, T. K. & Wu, Y. L. Mapping immune cell infiltration using restricted diffusion MRI. Magn. Reson. Med. 77, 603–612 (2017).
pubmed: 26843524
doi: 10.1002/mrm.26143
Yeh, F., Verstynen, T. D., Wang, Y., Fernández-Miranda, J. C. and Tseng, W. I. Deterministic diffusion fiber tracking improved by quantitative anisotropy, PloS ONE, 8, 11 (2013).
Fortin, J. P. et al. Harmonization of multi-site diffusion tensor imaging data. Neuroimage 161, 149–170 (2017).
pubmed: 28826946
doi: 10.1016/j.neuroimage.2017.08.047
Qualls, C., Bliwise, N. & Stringer, A. “Short forms of the Benton judgment of line orientation test: Development and psychometric properties,”. Arch. Clin. Neuropsychol. 15, 159–163 (2000).
pubmed: 14590559
Yesavage, J. Geriatric depression scale. Psychopharmacol. Bull 24, 709–711 (1988).
pubmed: 3249773
Brandt, J. The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. Clin. Neuropsychol. 5, 125–142 (1991).
doi: 10.1080/13854049108403297
Wechsler, D. Wechsler Adult Intelligence Scale--Fourth Edition (WAIS-IV). (Pearson Assessments, San Antonio, 2008).
Goetz, C. et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov. Disord.: Off. J. Mov. Disord. Soc. 23, 2129–2170 (2008).
doi: 10.1002/mds.22340
Nasreddine, Z. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005).
pubmed: 15817019
doi: 10.1111/j.1532-5415.2005.53221.x
Spielberger, C., Sydeman, S., Owen, A. and Marsh, B. Measuring anxiety and anger with the State-Trait Anxiety Inventory (STAI) and the State-Trait Anger Expression Inventory (STAXI), in The Use of Psychological Testing for Treatment Planning and Outcomes Assessment, New York, 993–1021 (Lawrence Erlbaum Associates Publishers, 1999).
Smith, A. Symbol digit modalities test, 1–22 (Western psychological services, Los Angeles, 1973).
Iturria-Medina, Y. et al. Integrating molecular, histopathological, neuroimaging and clinical neuroscience data with NeuroPM-box, Commun. Biol. 4, 614 (2021).